Testing low-dose radiation with immunotherapy and chemo for early oral cancer
Part of Cancer clinical trials.
This trial tests if combining a low dose of radiation with an immunotherapy drug (adebrelimab) and a chemotherapy drug (albumin-bound paclitaxel) before surgery can help treat early-stage oral squamous cell carcinoma. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have been diagnosed with early-stage (stage I-II) oral squamous cell cancer that hasn't spread to lymph nodes or other parts of the body.
- You are generally healthy enough for daily activities (ECOG score 0-1).
- Your major organs (bone marrow, liver, kidneys, heart) are working well, as shown by recent blood tests and scans.
- You cannot have had certain previous treatments, like taxane chemotherapy, or received other cancer treatments in the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, immunotherapy, and chemotherapy for people with advanced oral squamous cell carcinoma (a type of mouth cancer) who have not had any prior cancer treatment. The goal is to see if this approach can shrink tumors safely.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Hear when a new Early-Stage Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.